Cargando…
Review of Adjuvant Therapies in Renal Cell Carcinoma: Evidence to Date
In 2018, there were 400,000 new cases of renal cell carcinoma (RCC) globally, with 175,000 deaths attributable to the disease. Three quarters of patients have potentially curable localised disease at diagnosis; however, recurrence rates are as high as 40% following surgery. There are currently no ad...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7721274/ https://www.ncbi.nlm.nih.gov/pubmed/33299326 http://dx.doi.org/10.2147/OTT.S174149 |